Skip to content
glp1.howSign in

Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs

Liraglutide (Victoza for diabetes, Saxenda for weight) is the first-generation GLP-1 — a daily injection with a roughly 13-hour half-life and generally more modest weight loss than the weekly drugs. Here's what makes it distinct and why it's still worth considering.

Updated Jul 18, 2026Evidence-backed

Most GLP-1 conversations now revolve around the weekly injectables — semaglutide and tirzepatide. Liraglutide is the one that came first, and it still works differently in a way that shapes daily life on it: you inject it every day, not every week. That single fact ripples through everything from how quickly it clears your system to how a missed dose plays out.

The first-generation GLP-1

Liraglutide was the GLP-1 receptor agonist that reached the weight-management world ahead of the drugs dominating the conversation now. It comes under two brand names: Victoza, approved for type 2 diabetes, and Saxenda, approved for chronic weight management. Same molecule, different approved uses and different maximum doses — Victoza tops out at 1.8 mg daily for blood-sugar control, while Saxenda titrates up to 3.0 mg daily for weight.

Why daily instead of weekly

The defining difference is dosing frequency. Semaglutide and tirzepatide are engineered to linger in the body for about a week, so one injection covers seven days. Liraglutide has an elimination half-life of roughly 13 hours — long enough for once-daily dosing, but nowhere near a week. That's why it's a daily injection, and why its whole rhythm feels different from the weekly drugs. (See our companion piece on how each drug's dose ladder is built for the titration specifics.)

How its results compare

Here's the honest part: liraglutide generally produces more modest weight loss than the newer weekly options. In the SCALE trial — the 56-week study behind Saxenda's approval — participants without diabetes taking 3.0 mg daily lost about 8.4 kg on average versus 2.8 kg on placebo, and roughly a third lost more than 10% of their body weight.

A later head-to-head trial put the two drugs side by side. STEP 8 compared weekly semaglutide 2.4 mg against daily liraglutide 3.0 mg over 68 weeks: semaglutide produced a mean 15.8% weight reduction versus 6.4% for liraglutide. That's a real gap, and it's the main reason liraglutide is no longer most people's first choice.

Why someone might still choose it

More modest average results don't make a drug obsolete. There are several practical reasons liraglutide still has a place:

  • Availability. During the stretches when semaglutide and tirzepatide were in shortage, liraglutide was often the GLP-1 you could actually fill.
  • Tolerability. Some people find the shorter-acting, daily profile easier to live with — a rough day's side effects don't linger for a full week the way a long-acting drug's can.
  • Insurance and cost. Formularies differ, and liraglutide (now including a first generic) may be covered when the newer drugs aren't.
  • Timing flexibility. A drug that clears in about a day rather than a week gives more control if you need to pause for a planned reason — for example, some people planning a pregnancy discuss stopping GLP-1s with their prescriber, and a shorter half-life means a shorter washout.

Which drug fits is a conversation for you and your prescriber — none of this is a ranking.

What the short half-life means day to day

The roughly 13-hour half-life is the thread connecting most of liraglutide's quirks. Because the drug clears relatively fast, the every-day schedule isn't as forgiving as a weekly shot's exact day can be — miss a day and blood levels drop off meaningfully. That also changes missed-dose logic: liraglutide's catch-up window is measured in hours, not days, and the "skip it and resume your schedule" threshold comes up fast (our missed-dose guide covers the general framework — and, as always, never double up to compensate).

The daily rhythm also shapes titration: liraglutide's dose increases are typically spaced by weeks rather than the monthly steps common with the weekly drugs, so the climb to a maintenance dose can feel faster. For some people the daily habit is the downside; for others, the shorter-acting profile is exactly why it suits them.

The bottom line

Liraglutide is the original GLP-1 for weight and diabetes: a daily injection with a roughly 13-hour half-life and generally more modest weight loss than the weekly drugs that followed. It stays relevant for availability, tolerability, cost, and timing reasons — and the daily cadence is the practical trade-off that comes with it.

This is general education and peer information, not medical advice — which GLP-1 and dose fit you is a conversation for your prescriber.

Trial evidence in this guide is drawn from PubMed-indexed research (SCALE, NEJM 2015; STEP 8, JAMA 2022); see the sources below for DOIs.

liraglutidevictozasaxendadosingdailyhalf-lifetreatment

Was this helpful?

Common questions

Questions people often ask about this topic.

  • What's the difference between Victoza and Saxenda?

    They're the same molecule — liraglutide — under two brand names with different approved uses and maximum doses. Victoza is approved for type 2 diabetes and tops out at 1.8 mg daily, while Saxenda is approved for chronic weight management and titrates up to 3.0 mg daily.

  • Why is liraglutide a daily injection when semaglutide and tirzepatide are weekly?

    It comes down to how long the drug stays in the body. Liraglutide has an elimination half-life of roughly 13 hours — long enough for once-daily dosing but nowhere near a week — while semaglutide and tirzepatide are engineered to linger for about a week, so one injection covers seven days.

  • How does liraglutide's weight loss compare to semaglutide's?

    Liraglutide generally produces more modest results. In the STEP 8 head-to-head trial over 68 weeks, weekly semaglutide 2.4 mg produced a mean 15.8% weight reduction versus 6.4% for daily liraglutide 3.0 mg. In the SCALE trial behind Saxenda's approval, participants lost about 8.4 kg on average versus 2.8 kg on placebo.

  • Why would anyone still choose liraglutide over the newer weekly drugs?

    Several practical reasons: it was often available when semaglutide and tirzepatide were in shortage; some people find the shorter-acting daily profile easier to tolerate since a rough day's side effects don't linger a full week; insurance may cover it (now including a first generic) when newer drugs aren't; and its shorter half-life gives more timing flexibility if you need to pause for a planned reason. Which drug fits is a conversation for you and your prescriber.

  • What happens if I miss a dose of liraglutide?

    Because liraglutide clears relatively fast, blood levels drop off meaningfully after a missed day — the catch-up window is measured in hours, not days, and the "skip it and resume your schedule" threshold comes up fast. As always, never double up to compensate, and confirm the specifics for your medication with your prescriber.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

2Supporting

Related terms

  • Saxenda — A brand of liraglutide, a daily-injection GLP-1 receptor agonist approved for chronic weight management and made by Novo Nordisk.
  • Victoza — A brand of liraglutide, a daily-injection GLP-1 receptor agonist approved for type 2 diabetes and made by Novo Nordisk.

Related guides

  • Safe sharps disposal for GLP-1 injectors — Every GLP-1 injection ends with a needle you have to put somewhere. Here's the FDA's two-step system: a proper sharps container (or an acceptable heavy-duty household stand-in), the short list of things never to do with a used needle, how to find your community's disposal rules, and what changes when you travel.
  • Common mistakes people make on GLP-1 medications — and how to avoid them — Most GLP-1 setbacks come from a short list of avoidable mistakes: treating it as a quick fix, neglecting protein and strength training, rushing the dose, under-hydrating, white-knuckling side effects, and going it alone. Here's the rundown of the most common ones, why they matter, and where to find the fix for each.
  • Shot day routines: how the GLP-1 community builds a weekly injection ritual — Once-weekly dosing turns "shot day" into a small ritual, and people build routines around it — picking the right day, warming the pen to reduce sting, rotating sites, eating lighter, logging everything, and heading off side effects before they start. Here's a tour of the common routines GLP-1 members swear by, and the reasons behind the ones that are actually worth copying.
  • GLP-1 microdosing: what it means, why people do it, and what the evidence actually says — "Microdosing" GLP-1s is all over social media — using much smaller doses than the label calls for, for weight maintenance, side-effect avoidance, cost, or vague wellness claims. Here's what the term actually means, the kernel of real medicine it borrows from, why no clinical trial has tested it, the specific risks of the DIY version, and the legitimate way to have a lower-dose conversation with your prescriber.